This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barbacid M. Neurotrophic factors and their receptors. Curr Opin Cell Biol 1995; 7:148–155.
Bongarzone I., Pierotti M.A., Monzini N., Mondellini P., Manenti G., Donghi R., Pilotti S., Grieco M., Santoro M., Fusco A., Vecchio G., Della Porta G. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 1989; 4:1457–1462.
Brodeur G.M., Maris J.M., Yamashiro D.J., Hogarty M.D., White P.S. Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 1997; 19:93–101.
Butti M.G., Bongarzone I., Ferraresi G., Mondellini P., Borrello M.G., Pierotti M.A. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics 1995; 28:15–24.
Cohen Y., Xing M., Mambo E., Guo Z., Wu G., Trink B., Seller U., Westra W.H., Ladenson P.W., Sidransky D. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95:625–627.
Davies A.M. The role of neurotrophins in the developing nervous system. J Neurobiol 1994; 25:1334–1348.
Descamps S., Toillon R.A., Adriaenssens E., Pawlowski V., Cool S.M., Nurcombe V., Le B., X, Boilly B., Peyrat J.P., Hondermarck H. Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem 2001; 276:17864–17870.
Di Marco E., Mathor M., Bondanza S., Cutuli N., Marchisio P.C., Cancedda R., De Luca M. Nerve growth factor binds to normal human keratinocytes through high and low affinity receptors and stim-ulates their growth by a novel autocrine loop. J Biol Chem 1993; 268:22838–22846.
Djakiew D., Delsite R., Plufg B., Wrathall J., Lynch J.H., Onoda M. Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res 1991; 51:3304–3310.
Greco A., Fusetti L., Miranda C., Villa R., Zanotti S., Pagliardini S., Pierotti M.A. Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene. Oncogene 1998; 16:809–816.
Greco A., Mariani C., Miranda C., Lupas A., Pagliardini S., Pomati M., Pierotti M.A. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol 1995; 15:6118–6127.
Greco A., Mariani C., Miranda C., Pagliardini S., Pierotti M.A. Characterization of the NTRK1 genomic region involved in chromosomal rearrangements generating TRK oncogenes. Genomics 1993a; 18:397–400.
Greco A., Miranda C., Pagliardini S., Fusetti L., Bongarzone I., Pierotti M.A. Chromosome 1 rear-rangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chrom Cancer 1997; 19:112–123.
Greco A., Orlandi R., Mariani C., Miranda C., Borrello M.G., Cattaneo A., Pagliardini S., Pierotti M.A. Expression of TRK-T1 oncogene induces differentiation of PC12 cells. Cell Growth Diff 1993b; 4:539–546.
Greco A., Pierotti M.A., Bongarzone I., Pagliardini S., Lanzi C., Della Porta G. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene 1992; 7:237–242.
Greco A., Villa R., Fusetti L., Orlandi R., Pierotti M.A. The Gly571Arg mutation, associated with the autonomic and sensory disorder CIPA, causes the inactivation of the NTRK1/NGF receptor. J Cell Physiol 2000; 182:127–133.
Greco A., Villa R., Pierotti M.A. Genomic organization of the human NTRK1 gene. Oncogene 1996; 13:2463–2466.
Greco A., Villa R., Tubino B., Romano L., Penso D., Pierotti M.A. A novel NTRK1 mutation associated with congenital insensitivity to pain anhidrosis. Am J Hum Genet 1999; 64:1207–1210.
Green D.M., Johnson C.P., Hagan H., Corbett A.H. The C-terminal domain of myosin-like protein 1 (Mlp1p) is a docking site for heterogeneous nuclear ribonucleoproteins that are required for mRNA export. Proc Natl Acad Sci U S A 2003; 100:1010–1015.
Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumours. Berlin, Heidelberg: WHO Second Edition, Springer-Verlag, 1988.
Hernandez L., Bea S., Bellosillo B., Pinyol M., Falini B., Carbone A., Ott G., Rosenwald A., Fernandez A., Pulford K., Mason D., Morris S.W., Santos E., Campo E. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am J Pathol 2002; 160:1487–1494.
Indo Y., Tsuruta M., Hayashida Y., Karim M.A., Otha K., Kawano T., Mitsubuchi H., Tonoki H., Awaya Y., Matsuda I. Mutations in TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nature Genet 1996; 13:485.
Ishikawa F., Takaku F., Nagao M., Sugimura T. Rat c-raf oncogene activation by a rearrangement that produces a fused protein. Mol Cell Biol 1987; 7:1226–1232.
Kaplan D.R., Martin-Zanca D., Parada L.F. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature 1991; 350:158–160.
Kaplan D.R., Miller F.D. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 2000; 10:381–391.
Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cance: gene evidence for constitutive activation of RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63:1454–1457.
Lamant L., Dastugue N., Pulford K., Delsol G., Mariame B. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 1999; 93:3088–3095.
Lupas A. Coiled coils: new structures and new functions. Trends Biochem Sci 1996; 21:375–382.
Lupas A., Van Dyke M., Stock J. Predicting coiled coilts from protein sequences. Science 1991; 252: 1162–1164.
Martin-Zanca D., Hughes S.H., Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 1986; 319:743–748.
Martin-Zanca D., Oskam R., Mitra G., Copeland T., Barbacid M. Molecular and Biochemical char-acterization of the human trk proto-oncogene. Mol Cell Biol 1989; 9:24–33.
Mencinger M., Aman P. Characterization of TFG in mus musculus and Caenorhabditis elegans. Biochem Biophys Res Comm 1999; 257:67–73.
Mencinger M., Panagopoulos I., Andreasson P., Lassen C., Mitelman F., Aman P. Characterization and chromosomal mapping of the human TFG gene involved in thyroid carcinoma. Genomics 1997; 41:372–331.
Miranda C., Minoletti F., Greco A., Sozzi G., Pierotti M.A. Refined localization of the human TPR gene to chromosome 1q25 by in situ hybridization. Genomics 1994; 23:714–715.
Miranda C., Di Virgilio M., Selleri S., Zanotti G., Pagliardini S., Pierotti M.A., Greco A. Novel pathogenic mechanisms of congenital insensitivity to pain with anhidrosis genetic disorder unveiled by functional analysis of neurotrophic tyrosine receptor kinase type1/nervw growth factor receptor mutations. J Biol Chem 2002a; 277:6455–6462.
Miranda C., Greco A., Miele C., Pierotti M.A., Van Obberghen E. IRS-1 and IRS-2 are recruited by TrkA receptor and oncogenic TRK-T1. J Cell Physiol 2001; 186:35–46.
Miranda C., Selleri S., Pierotti M.A., Greco A. The M581V mutation, associated with a mid form of Congenital Insensitivity to Pain with Anhidrosis, causes partial inactivation of the NTRK1 receptor. J Invest Dermatol 2002b; 119:976–979.
Miranda C., Zanotti G., Pagliardini S., Ponzetto C., Pierotti M.A., Greco A. Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activity. Oncogene 2002c; 21:8334–8339.
Nakamura K., Johnson G.L. PB1 domains of MEKK2 and MEKK3 interact with the MEK5 PB1 domain for activation of the ERK5 pathway. J Biol Chem 2003; 278:36989–36992.
Nikiforova M.N., Stringer J.R., Blough R., Medvedovic M., Fagin J.A., Nikiforov Y.E. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 2000; 290:138–141.
Otten U., Ehrhard P., Peck R. Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci USA 1989; 86:10059–10063.
Park M., Dean M., Cooper C.S., Schmidt M., O’Brien S.J., Blair D.G., Vande Woude G.F. Mechanism of met oncogene activation. Cell 1986; 45:895–904.
Pierotti M.A., Bongarzone I., Borrello M.G., Greco A., Pilotti S., Sozzi G. Cytogenetics and molecular genetics of the carcinomas arising from the thyroid epithelial follicular cells. Genes Chrom Cancer 1996; 16:1–14.
Ranzi V., Meakin S.O., Mondellini P., Pierotti M.A., Greco A. The signaling adapters FRS2 and FRS3 are substrates of the thyroid TRK oncoproteins. Endocrinology 2003; 144:922–928.
Reuther G.W., Lambert Q.T., Caligiuri M.A., Der C.J. Identification and characterization of an acti-vating TrkA deletion mutation in acute myeloid leukemia. Mol Biol Cell 2000; 20:8655–8666.
Roccato E., Miranda C., Ranzi V., Gishizky M.L., Pierotti M.A., Greco A. Biological activity of the thyroid TRK-T3 oncogene requires signaling through Shc. Br J Cancer 2002; 87:645–653.
Roccato E., Pagliardini S., Cleris L., Canevari S., Formelli F., Pierotti M.A., Greco A. Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation. Oncogene 2003; 22:807–818.
Rodrigues G.A., Park M. Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol Cell Biol 1993; 13:6711–6722.
Shibata S., Matsuoka Y., Yoneda Y. Nucleocytoplasmic transport of proteins and poly(A) + RNA in reconstituted Tpr-less nuclei in living mammalian cells. Genes Cells 2002; 7:421–434.
Soares P., Trovisco V., Rocha A.S., Lima J., Castro P., Preto A., Maximo V., Botelho T., Seruca R., Sobrinho-Simoes M. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22:4578–4580.
Terasawa H., Noda Y., Ito T., Hatanaka H., Ichikawa S., Ogura K., Sumimoto H., Inagaki F. Structure and ligand recognition of the PB1 domain: a novel protein module binding to the PC motif. EMBOJ 2001; 20:3947–3956.
Weeraratna A.T., Dalrymple S.L., Lamb J.C., Denmeade S.R., Miknyoczki S.J., Dionne C.A., Isaacs J.T. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin Cancer Res 2001; 7:2237–2245.
Weier H.-U.G., Rhein A.P., Shadravan F., Collins C., Polikoff D. Rapid physical mapping of the human trk protooncogene (NTRK1) to human chromosome 1q21–q22 by P1 clone selection, fluorescence in situ hybridization (FISH), and computer-assisted microscopy. Genomics 1995; 26:390–393.
Wilton S.D., Eyre H., Akkari P.A., Watkins H.C., MacRae C., Laing N.G., Callen, DC. Assignment of the human a-tropomyosin gene TPM3 to 1q22-&τ;q23 by fluorescence in situ hybridisation. Cytogenet Cell Genet 1995; 68:122–124.
Yang T.T., Namba H., Hara T., Takmura N., Nagayama Y., Fukata S., Ishikawa N., Kuma K., Ito K., Yamashita S. p53 induced by ionizing radiation mediates DNA end-jointing activity, but not apoptosis of thyroid cells. Oncogene 1997; 14:1511–1519.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science + Business Media, Inc.
About this chapter
Cite this chapter
Greco, A., Roccato, E., Pierotti, M.A. (2005). TRK Oncogenes in Papillary Thyroid Carcinoma. In: Farid, N.R. (eds) Molecular Basis of Thyroid Cancer. Cancer Treatment and Research, vol 122. Springer, Boston, MA. https://doi.org/10.1007/1-4020-8107-3_12
Download citation
DOI: https://doi.org/10.1007/1-4020-8107-3_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4020-8106-4
Online ISBN: 978-1-4020-8107-1
eBook Packages: MedicineMedicine (R0)